Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by carduon May 08, 2010 11:14am

490 Views

Post# 17077242

Shareholder's value!

I was listening to a CEO of a major company on BNN the other day and was struck by an emphatic statement he made. He was discussing the future development of the company and made the following point,"...the main thrust going forward is to INCREASE value to the shareholders of this company". How I wish the same (sincere)commitment was forthcoming from Mr. Thompson.

Three days to find out what the h*ll is happening, hopefully.

Bullboard Posts

Covalon Technologies posts third profitable quarter in a row